Orchestra BioMed Holdings (OBIO) Net Margin (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Net Margin of 18778.18% for Q1 2026, down 1661747.0% year-over-year from N/an in Q1 2025, and down 90912.61% quarter-over-quarter from 20.68% in Q4 2025.
Orchestra BioMed Holdings (OBIO) Net Margin (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Net Margin for 5 consecutive years, with 18778.18% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin fell 1661747.0% year-over-year to 18778.18%; the TTM figure through Mar 2026 stood at 172.26% (up 251877.0% YoY), while the FY2025 annual figure was 158.16%, up 215511.0% from the prior year.
- Net Margin retreated to 18778.18% in Q1 2026 per OBIO's latest filing, from 20.68% in the prior quarter.
- Across five years, Net Margin topped out at 20.68% in Q4 2025 and bottomed at 18778.18% in Q1 2026.
- Historically, Net Margin has averaged 3359.54% across 5 years, with a median of 2160.71% in 2025.
- Annual changes were most pronounced in 2025 — Net Margin soared 638352 bps — and 2026, when it slumped 1661747 bps.
- Orchestra BioMed Holdings' Net Margin stood at 914.6% in 2022, then slumped by 421 bps to 4763.74% in 2023, then sank by 34 bps to 6362.85% in 2024, then soared by 100 bps to 20.68% in 2025, then sank by 90913 bps to 18778.18% in 2026.
- Business Quant data shows OBIO's Net Margin at 18778.18% in Q1 2026, 20.68% in Q4 2025, and 2385.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -27,362.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27,362.50% |
| Mar 31, 2026 | -18,778.18% |
| Dec 31, 2025 | 20.68% |
| Sep 30, 2025 | -2,385.37% |
| Jun 30, 2025 | -2,579.90% |
| Mar 31, 2025 | -2,160.71% |
| Dec 31, 2024 | -6,362.85% |
| Sep 30, 2024 | -1,785.41% |
| Jun 30, 2024 | -3,237.53% |
| Mar 31, 2024 | -2,548.06% |
| Dec 31, 2023 | -4,763.74% |
| Sep 30, 2023 | -5,255.13% |
| Jun 30, 2023 | -1,853.33% |
| Mar 31, 2023 | -1,021.99% |
| Dec 31, 2022 | -914.60% |
| Sep 30, 2022 | -898.88% |
| Jun 30, 2022 | -1,967.83% |
| Mar 31, 2022 | -619.40% |